NPS Pharmaceuticals (NPSP) 27.44 $NPSP
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
NPS Pharmaceuticals (NPSP) Jumps: Stock Up 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 7:51AM CDT
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri May 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pre-Market Review on Active Stocks -- Research on Louisiana-Pacific, ArcelorMittal, NPS Pharma, and Investors Bancorp
PR Newswire - Fri May 09, 12:28PM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,550.97, up 0.20% and the NASDAQ Composite closed at 4,051.50, down 0.40%. The S&P 500 edged 0.14% lower, to finish the day at 1,875.63. During the session, five out of ten sectors finished on a positive note. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Louisiana-Pacific Corporation (NYSE: LPX), ArcelorMittal (NYSE: MT), NPS Pharmaceuticals Inc. (NASDAQ: NPSP) and Investors Bancorp Inc. (NASDAQ: ISBC). Free technical research on LPX, MT, NPSP and ISBC can be downloaded upon signing up at:
Wider-Than-expected Loss at NPS Pharma, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 11:00AM CDT
Shares of NPS Pharma (NPSP) declined following the reduced outlook on Gattex.
Why NPS Pharmaceuticals (NPSP) Stock Is Down This Afternoon
at The Street - Thu May 08, 1:27PM CDT
Shares of NPS Pharmaceuticals (NPSP) are lower by -7.54% after the company cut its 2014 forecast and now sees 2014 sales of $100 million to $110 million, down from the previous forecast of $110 million to $120 million.
Why NPS Pharmaceuticals Inc. Shares Slumped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 11:49AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NPS Pharmaceuticals , a biopharmaceutical...
NPS Pharma Blames Winter, Drug Stops for Weak First Quarter, Reduced Guidance
at The Street - Thu May 08, 7:47AM CDT
Gattex sales in the March quarter missed consensus expectations and 2014 sales guidance was reduced by $10 million.
NPS Pharma Reports First-Quarter 2014 Financial Results
Business Wire - Thu May 08, 7:05AM CDT
--Full-year net sales guidance revised to $100 to $110 million from $110 to $120 million to reflect impact of delays in January and February sales
NPS Pharma among 100 Best Places to Work in New Jersey for Third Consecutive Year
Business Wire - Tue May 06, 7:31AM CDT
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, has been named one of the Best Places to Work in New Jersey for the third consecutive year. The honor is awarded annually by New Jersey's weekly business journal, NJBIZ, to the state's top 100 companies demonstrating dedication to their employees' growth and quality of life.
Watch for NPS Pharmaceuticals to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Mon May 05, 5:40PM CDT
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $26.37 to a high of $29.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $27.86 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NPS Pharmaceuticals to Report First Quarter 2014 Financial Results
Business Wire - Tue Apr 29, 3:10PM CDT
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its first quarter 2014 financial results on Thursday, May 8, 2014 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.
Kidney Transplantation - Pipeline Review, H1 2014
M2 - Tue Apr 29, 8:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sxcd3n/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Transplantation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Transplantation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Pharming Group N.V. - Astellas Pharma Inc. - Shire Plc - 4SC AG - Veloxis Pharmaceuticals A/S - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - Hansa Medical AB - Digna Biotech, S.L. - Viron Therapeutics, Inc. - Opsona Therapeutics Ltd. - Angion Biomedica Corp. - NovImmune SA - Tolera Therapeutics, Inc. - Pharmicell Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sxcd3n/kidney
NPS Pharmaceuticals Shares Down 24.5% Since SmarTrend's Sell Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 28, 4:54PM CDT
SmarTrend identified a Downtrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 6th, 2014 at $33.22. In approximately 2 months, NPS Pharmaceuticals has returned 24.49% as of today's recent price of $25.08.
NPS Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference
Business Wire - Mon Apr 28, 3:10PM CDT
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 13, 2014 at 8:40 a.m. PT. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS website at http://www.npsp.com/calendar.
This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:05PM CDT
It's only Tuesday and this has already been an exciting week in the health-care sector. I'm speaking of the news this weekend that pharma giant Pfizer reportedly considered making a $101 billion bid for U.K.-based rival AstraZeneca , a 27%...
25.3% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 21, 11:00AM CDT
SmarTrend identified a Downtrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 6th, 2014 at $33.22. In approximately 2 months, NPS Pharmaceuticals has returned 25.26% as of today's recent price of $24.83.
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
The ongoing market correction has taken a serious toll on biotech stocks, especially among companies early in their development. The iShares Nasdaq Biotech Index , for instance, is down over 15% in the past month alone. Market corrections (and bull...
NPS Pharmaceuticals Falls 1.43% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 5:35PM CDT
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $22.90 to a high of $25.04. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $23.51 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
NPS Pharmaceuticals (NPSP) Jumps: Stock Up 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 7:51AM CDT
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 14% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri May 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pre-Market Review on Active Stocks -- Research on Louisiana-Pacific, ArcelorMittal, NPS Pharma, and Investors Bancorp
PR Newswire - Fri May 09, 12:28PM CDT
The markets on Thursday, May 08, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,550.97, up 0.20% and the NASDAQ Composite closed at 4,051.50, down 0.40%. The S&P 500 edged 0.14% lower, to finish the day at 1,875.63. During the session, five out of ten sectors finished on a positive note. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Louisiana-Pacific Corporation (NYSE: LPX), ArcelorMittal (NYSE: MT), NPS Pharmaceuticals Inc. (NASDAQ: NPSP) and Investors Bancorp Inc. (NASDAQ: ISBC). Free technical research on LPX, MT, NPSP and ISBC can be downloaded upon signing up at:
Wider-Than-expected Loss at NPS Pharma, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 11:00AM CDT
Shares of NPS Pharma (NPSP) declined following the reduced outlook on Gattex.
Why NPS Pharmaceuticals (NPSP) Stock Is Down This Afternoon
at The Street - Thu May 08, 1:27PM CDT
Shares of NPS Pharmaceuticals (NPSP) are lower by -7.54% after the company cut its 2014 forecast and now sees 2014 sales of $100 million to $110 million, down from the previous forecast of $110 million to $120 million.
Why NPS Pharmaceuticals Inc. Shares Slumped
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 11:49AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NPS Pharmaceuticals , a biopharmaceutical...
NPS Pharma Blames Winter, Drug Stops for Weak First Quarter, Reduced Guidance
at The Street - Thu May 08, 7:47AM CDT
Gattex sales in the March quarter missed consensus expectations and 2014 sales guidance was reduced by $10 million.
NPS Pharma Reports First-Quarter 2014 Financial Results
Business Wire - Thu May 08, 7:05AM CDT
--Full-year net sales guidance revised to $100 to $110 million from $110 to $120 million to reflect impact of delays in January and February sales
NPS Pharma among 100 Best Places to Work in New Jersey for Third Consecutive Year
Business Wire - Tue May 06, 7:31AM CDT
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, has been named one of the Best Places to Work in New Jersey for the third consecutive year. The honor is awarded annually by New Jersey's weekly business journal, NJBIZ, to the state's top 100 companies demonstrating dedication to their employees' growth and quality of life.
Watch for NPS Pharmaceuticals to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Mon May 05, 5:40PM CDT
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $26.37 to a high of $29.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $27.86 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NPS Pharmaceuticals to Report First Quarter 2014 Financial Results
Business Wire - Tue Apr 29, 3:10PM CDT
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its first quarter 2014 financial results on Thursday, May 8, 2014 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.
Kidney Transplantation - Pipeline Review, H1 2014
M2 - Tue Apr 29, 8:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sxcd3n/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Transplantation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Transplantation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Quark Pharmaceuticals, Inc. - Pharming Group N.V. - Astellas Pharma Inc. - Shire Plc - 4SC AG - Veloxis Pharmaceuticals A/S - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - Hansa Medical AB - Digna Biotech, S.L. - Viron Therapeutics, Inc. - Opsona Therapeutics Ltd. - Angion Biomedica Corp. - NovImmune SA - Tolera Therapeutics, Inc. - Pharmicell Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sxcd3n/kidney
NPS Pharmaceuticals Shares Down 24.5% Since SmarTrend's Sell Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 28, 4:54PM CDT
SmarTrend identified a Downtrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 6th, 2014 at $33.22. In approximately 2 months, NPS Pharmaceuticals has returned 24.49% as of today's recent price of $25.08.
NPS Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference
Business Wire - Mon Apr 28, 3:10PM CDT
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 13, 2014 at 8:40 a.m. PT. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS website at http://www.npsp.com/calendar.
This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:05PM CDT
It's only Tuesday and this has already been an exciting week in the health-care sector. I'm speaking of the news this weekend that pharma giant Pfizer reportedly considered making a $101 billion bid for U.K.-based rival AstraZeneca , a 27%...
25.3% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 21, 11:00AM CDT
SmarTrend identified a Downtrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 6th, 2014 at $33.22. In approximately 2 months, NPS Pharmaceuticals has returned 25.26% as of today's recent price of $24.83.
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
The ongoing market correction has taken a serious toll on biotech stocks, especially among companies early in their development. The iShares Nasdaq Biotech Index , for instance, is down over 15% in the past month alone. Market corrections (and bull...
NPS Pharmaceuticals Falls 1.43% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 5:35PM CDT
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $22.90 to a high of $25.04. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $23.51 on volume of 2.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
